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Abstract
Introduction
As studies of biomarkers of tuberculosis (TB) disease provide hope for a simple, point-of-
care test, we aimed to synthesize evidence on biomarkers for diagnosis of TB in children
and compare their accuracy to published target product profiles (TPP).
Methods
We conducted a systematic review of biomarkers for diagnosis of pulmonary TB in exclu-
sively paediatric populations, defined as age less than 15 years. PubMed, EMBASE and
Web of Science were searched for relevant publications from January 1, 2000 to November
27, 2017. Studies using mixed adult and paediatric populations or reporting biomarkers for
extrapulmonary TB were excluded. Study quality was assessed using the Quality Assess-
ment of Diagnostic Accuracy Studies—2 (QUADAS-2) framework. No meta-analysis was
done because the published childhood TB biomarkers studies were mostly early stage stud-
ies and highly heterogeneous.
Results
The 29 studies included in this systematic review comprise 20 case-control studies, six
cohort studies and three cross-sectional studies. These studies reported diverse and het-
erogeneous forms of biomarkers requiring different types of clinical specimen and laboratory
assays. Majority of the studies (27/29 [93%]) either did not meet the criteria in at least one of
the four domains of the QUADAS-2 reporting framework or the assessment was unclear.
However, the diagnostic performance of biomarkers reported in 22 studies met one or both
of the WHO-recommended minimal targets of 66% sensitivity and 98% specificity for a new
diagnostic test for TB disease in children, and/or 90% sensitivity and 70% specificity for a tri-
age test.
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Conclusion
We found that majority of the biomarkers for diagnosis of TB in children are promising but
will need further refining and optimization to improve their performances. As new data are
emerging, stronger emphasis should be placed on improving the design, quality and general
reporting of future studies investigating TB biomarkers in children.
Introduction
Childhood tuberculosis (TB) is estimated to constitute approximately 5% of the TB caseload in
low TB burden countries compared to an estimated 20–40% in high-burden countries [1, 2].
However, notification of TB in children and subsequently deriving an accurate estimate of the
disease burden remain notoriously inaccurate. This is primarily because of the greater chal-
lenge in confirming the diagnosis of paediatric TB due to the paucibacillary nature of TB dis-
ease in children and difficulty in obtaining good quality respiratory specimen [3, 4]. In
support of this assertion, it is estimated that more than two-third of all childhood TB cases are
either unreported or undiagnosed, while 96% of the 239,000 children who died from TB in
2015 were not on treatment [5, 6].
The sensitivity of sputum smear microscopy in childhood TB is less than 15%, even with
optimized methods such as centrifugation of samples and use of fluorescent microscopy [7].
While culture of Mycobacterium tuberculosis (M.tb) in biological samples is more sensitive
than smear microscopy, bacteriological confirmation of paediatric TB by both mycobacterial
growth indicator tube (MGIT) liquid culture and Lo¨wenstein-Jensen (LJ) solid media seldom
exceeds 40%, including when using gastric aspirates and induced sputum [8, 9].
Although in adult studies the sensitivity and specificity of Xpert MTB/RIF (Cepheid, USA)
is comparable to that of liquid culture [10–12], data from paediatric studies suggest that the
sensitivity of Xpert is lower in children, and substantially lower among ambulant paediatric
populations compared to paediatric inpatients [13–19]. In 2017, the World Health Organiza-
tion (WHO) endorsed the use of Xpert MTB/RIF Ultra cartridge (Ultra), based on the findings
from a large multi-centre non-inferiority diagnostic accuracy study in adults with signs and
symptoms of pulmonary TB [20]. The study reported that Ultra had 5% higher sensitivity rela-
tive to Xpert MTB/RIF (95% CI: +2.7, +7.8) but 3.2% lower specificity (95% CI: -2.1, -4.7),
with sensitivity gains highest among smear-negative, culture-positive patients and in HIV-
infected patients [21]. Preliminary data on the accuracy of Ultra testing of sputum for diagno-
sis of pulmonary TB in hospitalized children reported that Ultra detected 75.3% of cases posi-
tive by culture on the same sample, while the performance of Ultra is comparable to that of
Xpert amongst children with a positive Xpert, Ultra or TB culture [22].
Diagnosis of childhood TB remains challenging with the current routine clinical and labo-
ratory diagnostic tools. Thus, the need for a new, preferably non-sputum based point-of-care
(POC) diagnostic tool that could give a rapid and accurate diagnosis of TB disease in children
is widely acknowledged. Although tests based on host immune response hold promise in this
regard, no immune-diagnostic has been developed into a POC test than can distinguish
between latent TB infection (LTBI) and TB disease, and more importantly between TB disease
and other respiratory infections. Both the tuberculin skin test (TST) and interferon (IFN)-γ
release assays (IGRA) fail to differentiate M.tb infection from TB disease [23–25].
Research into TB biomarkers has gained prominence due to the lack of suitable tests based
on detection of the pathogen [26], and their potential for translation into a non-sputum based
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POC test [27]. The majority of studies investigating novel TB biomarkers utilized adult popu-
lations, while TB diagnostic research studies are traditionally conducted in adults with the
findings usually extrapolated to children. It is unlikely that adult findings can be accurately
extrapolated to paediatric populations given the considerable differences in clinical presenta-
tion, pathology and underlying immune responses to M.tb between adults and children [28].
However, studies of TB biomarkers in children are now emerging, and there is growing advo-
cacy to include children as early as possible in research for new diagnostics with greater atten-
tion to addressing particular diagnostic challenges for children [29].
Therefore, the aim of this systematic review was to evaluate emerging biomarkers for diag-
nosis of TB in children aged less than 15 years, and to compare their diagnostic accuracy to the
WHO-endorsed target product profiles (TPP) recommended for potential new diagnostics for
TB in children [27].
Materials and methods
Search strategy and selection criteria
We conducted a systematic review of biomarkers and multi-marker biosignatures for diagno-
sis of active tuberculosis in exclusively paediatric study subjects, defined as age less than 15
years, in studies published between January 1, 2000 and November 27, 2017. A copy of the pro-
tocol for this systematic review is included in the Supporting Information (S1 File). PubMed,
EMBASE, and Web of Science were searched for relevant publications. In the case of PubMed,
searches including medical subject headings (MeSH), “text words” (tw) and titles (ti) were
used. In PubMed, the ‘English’ filter was not used. For EMBASE and Web of Science, ‘English’
and ‘Human’ filters were used. For each database, the search term was transposed as appropri-
ate. The PubMed search term used was as follows:
((((tuberculosis[ti] OR TB[ti]) AND (child[tw] OR pediat[tw])) ((("biological markers"[-
mesh] OR biological marker[tw] OR biomarker[tw] OR biosignature[tw]) NOT (tumour
[tw] OR tumor[tw] OR "tumor markers, biological"[mesh])) OR (miRNA[tw] OR microRNA
[tw] OR proteom[tw] OR transcriptom[tw] OR immunoassay[tw] OR immunoassay
[mesh] OR LAM[tw] OR lipoarabinomannan[tw] OR ("immunologic tests"[mesh] AND
diagnos[tw]) OR ((mycolic acid[tw] OR glycolipid[tw]) AND (diagnos[tw] OR detect
[tw])) OR (cytokine[tw] AND diagnos[tw]) )) NOT (animals[mesh] NOT humans[mesh])))
We structured the preparation and reporting of our systematic review according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [30].
Only studies of humans or that used human biological samples were eligible for inclusion. Bio-
markers and multi-marker biosignatures, of immunological and microbiological origin, were
included. Studies using adult or mixed adult and paediatric populations were excluded. Studies
reporting biomarkers for extra-pulmonary TB (EPTB) detection were excluded. Index tests
that required imaging techniques or detection from bacterial culture were excluded. As sys-
tematic reviews for interferon-gamma release assays (IGRA) and mycobacterial DNA (e.g.
GeneXpert MTB/RIF, TB-LAMP) already exist [18, 31–33], these biomarkers were not
included in our study. Studies published in English and French were eligible for inclusion.
Publications were screened by title and abstract by two reviewers (TT, EM) before full-text
screening. TT and EM conferred to determine appropriateness of all selected articles.
Data extraction
The form utilized for data extraction was piloted for a separate systematic review (MacLean E.
et al., unpublished) and further refined for this systematic review. For all eligible articles, dou-
ble data extraction was performed by TT and EM using the structured Google form. A list of
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the fields for data extraction and the structured Google form used are included in the Support-
ing Information (S2 File).
Assessment of study quality
Two reviewers (TT, EM) assessed the quality of the studies using specific sets of criteria within
four domains of the Quality Assessment of Diagnostic Accuracy Studies– 2 (QUADAS-2)
framework [34]. As per QUADAS-2 guidelines, the selected questions were those deemed
most relevant for identifying biases for studies included in the review. Each criterion was clas-
sified as either “Yes”, “No”, or “Unclear” when applied to the information that is available in
the publications, as described in Table 1.
Diagnostic accuracy
Target product profiles for new TB diagnostic tests in adults and children have been published
[27]. We reviewed the diagnostic performances of the biomarkers, where reported, to highlight
biomarkers that met the WHO-recommended minimal targets of 66% sensitivity and 98%
specificity for a new diagnostic test for TB disease in children, and/or 90% sensitivity and 70%
specificity for a triage test.
We summarized the evidence by a review of the methodological characteristics of the pub-
lished studies including immunological properties of the biomarkers, clinical samples and
assays required, as well as assessment of study quality and reported diagnostic accuracy as
Table 1. QUADAS-2 framework for quality assessment.
Domain 1: Patient selection [could their selection have introduced bias?]
Signaling question 1: was a consecutive or random sample of patients enrolled?
Yes: publication explicitly states sampling strategy is consecutive or random or describes it with sufficient clarity
such that this conclusion is clearly evident.
No: Convenience sampling; purposive sampling.
Unclear: Inadequate description to conclusively know sampling was consecutive or random.
Applicability: are there concerns that the included patients and setting do not match the review question?
Domain 2: Index test [could the conduct or interpretation of the index test have introduced bias?]
Signaling Question 2: were the index test results interpreted without knowledge of the results of the reference
standard? (i.e. blinding)
Yes: Conduct/interpretation of the index test was blinded.
No: Unblinded conduct/interpretation.
Unclear: Inadequate description of blinding.
Applicability: are there concerns that the index test, its conduct, or interpretation differ from the review question?
Domain 3: Reference standard [could the reference standard, its conduct, or its interpretation have introduced
bias?]
Signaling Question 3: is the reference standard likely to correctly classify the target condition?
Yes: Culture-based reference standard (could be composite standard) OR citation of valid diagnostic algorithm, e.g.
American Thoracic Society
No: Reference standard did not include culture
Unclear: Inadequate description of reference standard to understand procedures
Applicability: are there concerns that the target condition as defined by the reference standard does not match the
question?
Domain 4: Flow and timing [could the patient flow have introduced bias?)
Signaling Question 4: were all patients included in the analysis?
Yes: All patients, after exclusions, were given the index test and reference tests
No: Unaccounted for patients, after exclusions, remain
Unclear: Inadequate description of patient flow through study
Note: Within the QUADAS-2 framework, there are four main domains in which bias can arise. We have chosen to
assess each domain using one signaling question. The notes about applicability are considerations to make when
considering overall quality of study and writing of manuscript.
https://doi.org/10.1371/journal.pone.0204029.t001
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described above. All data generated during this study are available from the corresponding
author on request.
Results
A total of 1235 records were identified through database search for studies published between
January 1, 2000 and November 27, 2017 and two additional records identified through refer-
ence lists. After removal of duplicates, 928 studies were screened using titles and abstracts; 98
full text articles were assessed for eligibility and 29 studies were eventually included in the sys-
tematic review (Fig 1).
Fig 1. PRISMA flowchart. Flow diagram of inclusion and exclusion of studies. Reasons for exclusion are: conference proceedings
and abstracts only; language (not English or French); technique (imaging-based, culture-based, commercial IGRA); reviews
(narrative review, systematic review, meta-analysis); or target of paper (epidemiological, molecular biology, cost effectiveness,
vaccine or drug study; biomarkers for detection of LTBI, prediction of disease progression or treatment monitoring). Studies that
only included adult patients were also excluded.
https://doi.org/10.1371/journal.pone.0204029.g001
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Characteristics of the studies
Table 2 summarizes the characteristics of the 29 studies in the systematic review, stratified by
study design, including the statistical parameters used to assess diagnostic performance of the
biomarkers when available [35–63]. Most of the studies (20/29 [69%]) were published between
2010 and 2017. Six of the published studies were cohort studies, while the others used either a
cross-sectional (n = 3) or case-control (n = 20) study design. Thirteen of the studies were con-
ducted in Asia (India = 7; China = 4; Bangladesh = 2), six in Europe, five in sub-Sahara Africa,
three in the Americas, and one Australia. The 29 studies reported diverse and heterogeneous
forms of biomarkers, which require different types of clinical specimen and utilized diverse
techniques and laboratory assays for identifying biomarkers. The biomarkers include host-
response markers comprising cytokine biomarkers (n = 7), cell surface biomarkers (n = 2),
mRNA transcript signatures (n = 5), micro RNA signatures (n = 2), antibodies (n = 9), and
metabolic signature (n = 1). Three studies investigated the utility of lipoarabinomannan
(LAM), a mycobacterial cell wall antigen, for diagnosis of childhood TB.
Study quality
Fig 2 shows the results from assessment of the quality of the studies in our systematic review
using four questions from the QUADAS-2 framework.
Patient selection (i.e. was a consecutive or random sample of patients enrolled?). Out of the
six cohort studies, three publications explicitly stated that consecutive samples of eligible sub-
jects were recruited [35, 38, 39]. Two studies were deemed to have used purposive sampling by
conducting biomarker analysis on a sub-selection of eligible subjects because of cost [37], or by
excluding IGRA positive children with other respiratory diseases in their discovery cohort [36].
The sampling strategy was not clearly described in the study by Tebruegge et al [40]. Only one
cross-sectional study and three out of 20 case-control studies reported that a consecutive sample
of eligible study subjects were enrolled [41, 50–52]. The remaining studies used either conve-
nience or purposive sampling strategy, or their sampling strategy was inadequately described.
Index test (i.e. was the conduct and interpretation of the index test blinded?). Four out of six
cohort studies explicitly stated that the conduct and interpretation of the index test was
blinded [35, 37, 38, 40]. None of the cross-sectional studies, and only two case-control studies
reported blinding of the conduct and interpretation of the index test results [57, 59].
Reference standard (i.e. is the reference standard likely to correctly classify the target condi-
tion?). All six cohort studies reported either a culture-based reference standard or a composite
reference standard with citation of a valid diagnostic algorithm. In contrast, two of the three
cross-sectional studies [42, 43], and six of the 20 case-control studies reported such a reference
standard [45, 56–60].
Patient flow and timing (were all patients included in the analysis?). All study subjects, after
exclusions, were given the index and reference tests in three cohort studies [35, 38, 39], while
some subjects could not be accounted for after exclusions in one study [40]. The description
was inadequate to clearly ascertain patient flow and timing in the other two cohort studies [36,
37]. Two cross-sectional and eight case-control studies showed that all patients were given the
index and reference tests after exclusions. One cross-sectional study and one case-control
study had patients that could not be accounted for after exclusions, while the description of
patient flow and timing was unclear in 11 case-control studies (Fig 2).
Diagnostic performance of biomarkers
Table 2 shows the accuracy estimates from all the studies that reported such data. Cytokine
biomarkers (IP-10, IL-2 and IL-13) in a case-control study by Armand et al demonstrated
Biomarkers for diagnosis of childhood tuberculosis: A systematic review
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sensitivity 80% and specificity 98%, while circulating microRNAs in another case-control
study by Zhou et al demonstrated sensitivity and specificity of 96% and 100% respectively [59,
63]. These biomarkers met both recommended minimal targets for a new diagnostic test.
Seven studies reported biomarkers that met both minimal TPP targets for a new triage test.
These include an IL-2 ELISPOT assay using recombinant M.tb antigen (secreted L-alanine
dehydrogenase [AlaDH]) that distinguished active TB and LTBI in a prospective study with a
Fig 2. Quality assessment of childhood TB biomarker studies. Results from assessment of the quality of each study in the systematic review using QUADAS-2
framework.
https://doi.org/10.1371/journal.pone.0204029.g002
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sensitivity of 100% and specificity of 81% [35]. Also, anti-BCG IgG secreted from M.tb-specific
plasma cells in a cross-sectional study of a new serological method (antibodies in lymphocyte
supernatants) that distinguished children with TB and other diseases demonstrated sensitivity
and specificity of 91% and 87% respectively [41]. Anti-Ag85C IgG [48], anti-BCG IgG [53],
microRNA-31 [60], circulating microRNAs [63], and cytokine biomarkers (IP-10, IL-5 and
IL-13) [59] reported in five of the case-control studies also met both minimal targets for a tri-
age test. However, 15 studies reported biomarkers that met just one of the minimal TPP targets
for a diagnostic or triage test. These biomarkers had sensitivity greater than 66% but specificity
less than the minimum of 98% set for a diagnostic test, or demonstrated sensitivity less than
90% but specificity that exceed the minimum of 70% for a new triage test [36–39, 43–47, 50,
54, 55, 57, 61, 62].
Discussion
The investigation and development of new TB diagnostics that are suitable for children has
been highlighted as a research priority for the End TB Strategy by the WHO [64]. We con-
ducted a systematic review of host-response and pathogen-derived biomarkers for diagnosis of
pulmonary TB disease in children, assessed quality of the included studies using the standard-
ised QUADAS-2 framework, and compared the diagnostic performances of the candidate bio-
markers to the published TPP recommended for new diagnostics for TB in children. In
general, we found that the published childhood TB biomarkers studies were mostly early-stage
studies and highly heterogeneous in terms of the specific type of biomarkers, clinical samples,
test methods, and reference standards used for diagnosis of pulmonary TB disease in children.
Therefore, we did not perform a meta-analysis.
An optimally designed diagnostic accuracy study is a prospective study with a blind com-
parison of the index and reference tests in consecutively recruited study subjects from a rele-
vant clinical population [65, 66]. If a diagnostic or triage test is to be applied in multiple
settings globally, then an optimal diagnostic accuracy study should also be multi-centre and/or
performed in multiple diverse geographical locations and populations. The majority of the
studies included in our systematic review used a case-control study design with the selection of
children defined as having TB disease and comparison groups that include healthy uninfected
or M.tb infected controls in most cases. Other studies enrolled children with suspected TB dis-
ease referred for investigations to ascertain their diagnosis, using either a cohort or cross-sec-
tional study design.
In our assessment of study quality, we found that most case-control studies were at an
unclear or high risk of bias. Included case-control studies typically either did not utilize a con-
secutive sampling strategy or the sampling strategy was unclear. Generally, it was unclear if
reported biomarker results were interpreted without knowledge of the results of the reference
standards. Most of the cohort and cross-sectional studies that recruited children with sus-
pected TB disease were also found to be at risk of bias because they either did not meet the cri-
teria or assessment was not clear in at least one QUADAS-2 domain.
The risk of overestimating diagnostic accuracy is much higher in studies that use a case-
control study design compared to other designs [67, 68]. A meta-analysis that investigated the
importance of 15 design features on estimates of diagnostic accuracy reported a relative diag-
nostic odds ratio (RDOR) of 4.9 especially in case control studies that included healthy controls
[69]. This mean diagnostic accuracy studies, particularly with the inclusion of healthy controls,
are likely to overestimate the diagnostic performance almost five times. The inclusion of
healthy controls introduces a design deficiency with lower occurrence of false-positive results
and thus increasing the specificity [70].
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The lack of a sensitive and specific reference standard for TB disease in children and of
standardized case definitions are known to constitute major challenges to the assessment of
accuracy of new diagnostic tools for childhood TB and for comparison of findings between
diagnostic studies [71, 72]. Therefore, we compared the reported diagnostic performances of
the biomarkers in our systematic review to the minimal targets of diagnostic performance rec-
ommended in a WHO-endorsed TPP for new TB diagnostic tests in children [27]. For a new
diagnostic test in children, a sensitivity of 66% for intrathoracic TB is considered optimal, as
this can currently be achieved using appropriate samples with Xpert, while the specificity
should be 98% specificity of a microbiological reference standard [18, 27]. The sensitivity of
a triage test should ideally be as high as that of the confirmatory test, but if a triage test could
be conducted at lower levels of care and is easier to do, then conceivably more children with a
higher likelihood of TB disease will be identified even if its sensitivity is lower than that of con-
firmatory test [27]. As such, the minimal sensitivity and specificity for a new triage test were
set at 90% and 70% respectively, in order to make such triage testing potentially cost-effective
in an implementation strategy.
Two case-control studies by Armand et al and Zhou et al reported cytokine biomarkers and
circulating microRNAs respectively, which met both minimal sensitivity and specificity targets
for a diagnostic or triage test [59, 63]. Overall, majority of the studies in this review reported
biomarkers that met one or both of the minimal sensitivity and specificity TPP targets for use
either as a diagnostic or triage test in children, which makes them promising. Biosignature
thresholds are often set to obtain an optimum accuracy using Receiver Operating Characteris-
tic (ROC) analysis [73, 74]. It is possible to re-optimise such thresholds for the biomarkers that
met just one of the minimal TPP targets, which could further increase the sensitivity or speci-
ficity of the biomarkers toward meeting both targets either for a diagnostic or triage test. How-
ever, these results should be interpreted cautiously while taking into consideration the
assessment of the quality of the individual studies and the potential for overestimation of diag-
nostic performance. In particular, findings from the case-control studies were deemed to have
a high risk of bias from assessment of their quality with very probable overestimation of the
reported diagnostic performances as discussed earlier.
A number of the studies in this review investigated and reported the utility of antibodies for
diagnosis of TB disease in children, including a novel serological assay called antibodies in
lymphocyte supernatant [41, 53]. Although the WHO encourages research in serological tests,
the organization has recommended against the use of the currently available commercial anti-
body-based tests for TB diagnosis [75].
Critically, the failure of almost all studies to clearly articulate the intended use case of their
biomarker-based diagnostic test, and to benchmark a biomarker towards it, has been
highlighted as one of the key issues that limit the impact and translation of biomarkers into
new diagnostic tests [76]. None of the studies in our systematic review clearly stated the
intended use of the reported biomarkers either as a diagnostic or triage test in children. Fur-
thermore, it has been suggested that an “ideal” biomarker (or set of biomarkers) that could be
developed into an accurate test for TB in children should fulfil the following characteristics: (i)
measurable in small volumes of readily obtainable samples such as blood, urine, stool, saliva,
etc.; (ii) identify M.tb with high sensitivity and specificity regardless of age, nutritional status
or HIV status; (iii) distinguish children with active TB disease from latently infected children
with other respiratory infections; and (iv) suitable for incorporation into a diagnostic platform
that would provide rapid results at or near the point of care [77]. While the performance of
majority of the biomarkers in this review is promising, most of the biomarkers will need fur-
ther refining and optimization while taking into consideration these methodological charac-
teristics of an “ideal” biomarker. As such, the biomarkers should be evaluated in stronger and
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better-designed prospective studies to limit risk of bias and to assess the feasibility of incorpo-
rating them into diagnostic platforms implementable in high TB burden settings.
Our systematic review has limitations. A formal assessment of publication bias was not per-
formed; existing methods like funnel plots or regression tests are not helpful for diagnostic
accuracy studies [78]. Additionally, it is always possible in a systematic review that relevant
publications were not identified in the search. However, the search term was constructed with
the assistance of a medical librarian, and the term was adapted from a previously used term
that was extensively calibrated (MacLean E. et al, unpublished).
Conclusions
The fact that most of the studies investigating TB biomarkers in children were published
within the last seven years supports the assertion that such data are now emerging. However,
the results from this systematic review suggest that stronger emphasis need to be placed on
improving the design, quality, and general reporting of studies investigating childhood TB bio-
markers. In particular, future research studies in this area should target their biomarker
research toward the TPP for a new diagnostic and/or triage test intended for use in children.
In addition, such studies should be multi-centre studies performed in diverse geographical
locations and populations, such that the diagnostic or triage test can be applied in multiple set-
tings globally. Another approach is to conduct side-by-side/parallel diagnostic accuracy studies
using prospective cohorts to benchmark different triage or diagnostic tests performance
against each other. These will enhance the reliability, comparability, and reproducibility of the
results, as well as the potential to translate the findings to the clinic while promoting more col-
laborative research. We hope that this systematic review will contribute to provide targeted
guidance for further scientific explorations toward the eventual development of the next-gen-
eration POC test for the rapid and accurate diagnosis of TB disease in children.
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